

West of Scotland Cancer Network
Skin Cancer MCN Work Plan 2025/2026

	Actions Required	Lead	Due Date
1.	Continue to engage with the Regional MDT Improvement Programme to optimise operational efficiency and effectiveness of the MDT		
1.1	Review the skin cancer data sets and definitions to ensure they remain fit for purpose and supplement the agreed 'core' data set for the application.	MCN Clinical Lead MCN&I Manager Local MDT Leads MCN Members	Dec 25
1.2	Work with MDT programme Board and eHealth colleagues to progress development of the MDT digital system ready for regional implementation, utilising the agreed tumour-specific dataset for skin cancers.		TBC
2.	Implement changes in the Regional Skin Cancer MDT following the MDT-FIT review		
2.1	Communicate MDT referral guidance and issue updated MDT proforma.	MCN Clinical Lead MCN&I Manager Regional MDT Chair	Apr 25
2.2	Establish quorate group of MDT clinicians and support the need for job planning discussions within services.		Sep 25
2.3	Monitor and ensure progress against actions identified through MDT-FIT process (not included in 2.1 and 2.2).		Mar 26
3.	Develop and maintain regional /national clinical guidelines to optimise patient care and lead on the development of national guidelines through collaboration with the Scottish Cancer Network (SCN) and colleagues in SCAN/NCA		
3.1	Co-ordinate the review of clinical management guidelines (CMGs) and clinical guidance documents (CGDs) in line with WoSCAN SOP. CMGs <ul style="list-style-type: none">Cutaneous Malignant Melanoma	MCN Clinical Lead MCN&I Manager MCN Members May be progressed through SCN	TBC

	Actions Required	Lead	Due Date
3.1	CGDs <ul style="list-style-type: none">• Malignant Melanoma Post Operative Lymphoedema Management Pathway• Develop SOP/Protocol for nodal basin US surveillance for melanoma, aligned to cutaneous melanoma national follow-up guideline• Pathway for screening for possible Lynch Syndrome/Muir Torre based on skin lesion pathology• Cutaneous Melanoma National Follow-up Guideline Regional Consensus Documents <ul style="list-style-type: none">• Pigmented Epithelial Melanocytoma Guidance (NEW)• Atypical Spitz (NEW)		May 25 Oct 25 Jun 25 Oct 25 May 25 Oct 25
3.2	Develop national CMG for Merkel Cell Carcinoma <ul style="list-style-type: none">• Complete approval process and publish on WoSCAN intranet site	MCN&I Manager MCN Members SCAN/NCA Clinicians	Apr 25
3.3	Clinical Management Pathway (CMP) <ul style="list-style-type: none">• Continue to collaborate with SCN in the development of a National CMP for Melanoma SACT.	MCN Clinical Lead MCN&I Manager MCN Members SCN	Mar 26
4.	Review the impact of neo-adjuvant immunotherapy on melanoma pathway		
4.1	Establish SLWG and convene meeting.	MCN Clinical Lead MCN&I Manager Advisory Board MCN Members SCAN/NCA Clinicians	Jun 25
4.2	Review current melanoma pathways and highlight potential pressure points relating to the administration of neo-adjuvant immunotherapy and consider changes to existing pathways in order to mitigate delays.		TBC
4.3	Update the current melanoma CMG to include the provision of neo-adjuvant immunotherapy.		TBC
4.4	If not addressed by SCN review, link with other regional networks (SCAN/NCA) with regards to the development of a national melanoma CMG.		TBC
5.	Optimise clinical pathways for patients with non-melanoma skin cancer		
5.1	Undertake initial discussions with clinical oncology regarding adjuvant immunotherapy for cutaneous squamous cell carcinoma (cSCC) and identify any actions to be progressed in this work plan year.	MCN Clinical Lead MCN&I Manager MCN Members	Aug 25
5.2	Explore potential collaboration with pharma regarding the development of an audit project to drive forward improvements in the care of patients with advanced cSCC.	MCN Clinical Lead MCN&I Manager MCN Members	Jun 25

	Actions Required	Lead	Due Date
6.	Promote a robust regional audit and research programme coordinated through the Skin Cancer MCN Research Subgroup to generate data and outcomes to improve patient pathways		
6.1	<ul style="list-style-type: none"> Identify areas where there is currently a lack of clinical evidence to support practice Support groups from all interested specialties in obtaining appropriate data to generate suitable analysis Where appropriate, encourage regional collaboration on projects to achieve patient numbers and standardise outcomes in cancer care across the network 	MCN Research Group MCN&I Manager Information Analyst	Mar 26
6.2	Present the first year of results from the retrospective audit of imaging follow-up in patients with melanoma, identify any actions arising from the audit and explore the opportunity to expand this audit across the network.	MCN Research Group MCN&I Manager Information Analyst	Jun 25
7.	Use cancer data to drive improvement in quality of care and outcomes		
7.1	Review QPI audit findings to identify variation in practice and highlight exceptions. <ul style="list-style-type: none"> Performance Summary Returns Assessed RCOG exception report produced Governance review and Interrogation of QPI exceptions Agreement of actions for inclusion in annual audit reports Input to the production of Annual Audit Report 	MCN Clinical Lead MCN&I Manager Information Manager Information Analyst	Dec 25
7.2	Identify requirements for further data analysis to aid understanding of variance and develop action/improvement plans.	MCN Clinical Lead MCN&I Manager MCN Clinicians Information Analyst	Jan 26
7.3	Monitor and ensure progress with regional and local board action/improvement plans. <ul style="list-style-type: none"> Conclusion of actions from QPI Exception Report 	MCN Clinical Lead MCN&I Manager MCN Members	Ongoing
7.4	Work with the local audit teams to explore where data collected for QPIs can provide insight into performance challenges not captured through QPI reporting.	MCN Clinical Lead MCN&I Manager MCN Members Information Analyst	Ongoing
8.	Re-establish the skin specialist nurses group as an independent subgroup of the Skin Cancer MCN		
8.1	Continue to communicate with CNSs across the region, with regular meetings where possible. Aim to formally reconstitute Nurses Group.	MCN Clinical Lead MCN&I Manager CNSs	Ongoing
8.2	Review initial workstreams and consider if particular pieces of work need to be absorbed by the Advisory Board. <ul style="list-style-type: none"> Holistic Needs Assessments 	MCN Clinical Lead MCN&I Manager	TBC

	Actions Required	Lead	Due Date
	<ul style="list-style-type: none"> Standardisation of patient information Pre-hab protocol General vitamin D advice 	CNSs	
9.0	Deliver regional education event which facilitates review of clinical audit data and promotes shared learning of current best practice and innovation		
9.1	Develop a focused programme for the event, addressing relevant key issues.	MCN Clinical Lead MCN&I Manager	Apr 25
9.2	Establish data requirements for the event and identify any arising from the event. <ul style="list-style-type: none"> Liaise with information team regards audit presentation requirements Liaise with information team if any further audit opportunities identified Ensure appropriate data sharing agreements issued, completed, agreed and passed to Information Team 	MCN Clinical Lead MCN&I Manager Information Analyst	Apr 25 May 25 May 25
9.3	Develop action plans arising from event and monitor progress of agreed actions. <ul style="list-style-type: none"> Record actions arising from discussion at event Develop action plans of same Issue action plans as appropriate Monitor progress of actions recorded 	MCN Clinical Lead MCN&I Manager	Jun 25
10.	Maintain regional service configuration map for skin cancers		
10.1	Update audit and activity data annually in line with QPI report publication and refresh as per any changes in configuration.	MCN&I Manager Information Analyst	Dec 25
11.	Watching brief		
11.1	Work with the Boards within the network to identify possible clinical pathway changes or improvements that might be realised with the use of the Digital Dermatology Programme and Active Clinical Referral Triage (ACRT). Particular focus will be on time to first treatment for patients with melanoma.	MCN Clinical Lead MCN&I Manager Advisory Board Information Analyst	Mar 26